Deals Of The Week: General Dynamics/Vangent, Paladin/Labopharm, Human Genome Sciences/4-Antibody
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.
The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. Pharma firms must identify products that will benefit from innovative pricing models, and then forge the types of collaborations that will support those models.